Cardiology Research

Gene Editing & Precision Cardiology

Gene editing technologies, such as CRISPR-Cas9, base editing, and prime editing, are revolutionizing precision cardiology by enabling targeted modification of disease-associated genes. These approaches aim to correct mutations linked to inherited cardiomyopathies, arrhythmias, and metabolic heart disorders. Precision cardiology leverages patient-specific genomic information to guide personalized therapy, optimize drug efficacy, and reduce adverse events. Integration of multi-omics, including genomics, transcriptomics, and proteomics, allows clinicians to understand complex disease mechanisms and tailor interventions accordingly. Preclinical studies demonstrate successful gene correction in cardiac tissues, and ongoing clinical trials explore safe delivery systems, including viral vectors and nanoparticles. Ethical, regulatory, and long-term safety considerations are critical for clinical adoption. Combining gene editing with regenerative medicine, pharmacogenomics, and AI-driven risk stratification enhances patient outcomes. This session highlights the convergence of molecular biology, cardiology, and personalized medicine, offering a roadmap for next-generation therapies that can prevent disease progression, restore cardiac function, and transform clinical care in cardiovascular genetics.